187 related articles for article (PubMed ID: 21115652)
21. Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus.
Kaliberov SA; Kaliberova LN; Buchsbaum DJ; Curiel DT
Cancer Gene Ther; 2014 Jul; 21(7):264-74. PubMed ID: 24903014
[TBL] [Abstract][Full Text] [Related]
22. Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck.
Zhu ZB; Mathis JM; Makhija SK; Lu B; Wang M; Ji S; Rivera AA; Rosenthal EL; Siegal GP; Curiel DT
Int J Oncol; 2007 Nov; 31(5):1213-22. PubMed ID: 17912450
[TBL] [Abstract][Full Text] [Related]
23. Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.
Chu QD; Sun G; Pope M; Luraguiz N; Curiel DT; Kim R; Li BD; Mathis JM
Surgery; 2012 Sep; 152(3):441-8. PubMed ID: 22853858
[TBL] [Abstract][Full Text] [Related]
24. Expression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model.
Cody JJ; Rivera AA; Lyons GR; Yang SW; Wang M; Ashley JW; Meleth S; Feng X; Siegal GP; Douglas JT
Lab Invest; 2013 Mar; 93(3):268-78. PubMed ID: 23358109
[TBL] [Abstract][Full Text] [Related]
25. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
[TBL] [Abstract][Full Text] [Related]
26. A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.
Zhang B; Liu Y; Zhang P; Wei Y; Yin X; Zheng J
Int J Gynecol Cancer; 2011 Dec; 21(9):1540-6. PubMed ID: 22080895
[TBL] [Abstract][Full Text] [Related]
27. E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer.
He XP; Su CQ; Wang XH; Pan X; Tu ZX; Gong YF; Gao J; Liao Z; Jin J; Wu HY; Man XH; Li ZS
Cancer Lett; 2009 Nov; 285(1):89-98. PubMed ID: 19481338
[TBL] [Abstract][Full Text] [Related]
28. Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo.
Rajecki M; Kanerva A; Stenman UH; Tenhunen M; Kangasniemi L; Särkioja M; Ala-Opas MY; Alfthan H; Sankila A; Rintala E; Desmond RA; Hakkarainen T; Hemminki A
Mol Cancer Ther; 2007 Feb; 6(2):742-51. PubMed ID: 17308070
[TBL] [Abstract][Full Text] [Related]
29. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.
Sonabend AM; Ulasov IV; Tyler MA; Rivera AA; Mathis JM; Lesniak MS
Stem Cells; 2008 Mar; 26(3):831-41. PubMed ID: 18192232
[TBL] [Abstract][Full Text] [Related]
30. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.
Toivonen R; Suominen E; Grenman R; Savontaus M
Oncol Rep; 2009 Jan; 21(1):165-71. PubMed ID: 19082458
[TBL] [Abstract][Full Text] [Related]
31. Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death.
Abou El Hassan MA; van der Meulen-Muileman I; Abbas S; Kruyt FA
J Virol; 2004 Nov; 78(22):12243-51. PubMed ID: 15507611
[TBL] [Abstract][Full Text] [Related]
32. hTERT-promoter-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells.
Onimaru M; Ohuchida K; Mizumoto K; Nagai E; Cui L; Toma H; Takayama K; Matsumoto K; Hashizume M; Tanaka M
Cancer Sci; 2010 Mar; 101(3):735-42. PubMed ID: 20059477
[TBL] [Abstract][Full Text] [Related]
33. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.
Tyler MA; Ulasov IV; Sonabend AM; Nandi S; Han Y; Marler S; Roth J; Lesniak MS
Gene Ther; 2009 Feb; 16(2):262-78. PubMed ID: 19078993
[TBL] [Abstract][Full Text] [Related]
34. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.
Oosterhoff D; Pinedo HM; Witlox MA; Carette JE; Gerritsen WR; van Beusechem VW
Gene Ther; 2005 Jun; 12(12):1011-8. PubMed ID: 15729367
[TBL] [Abstract][Full Text] [Related]
35. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
36. A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.
Kim KH; Ryan MJ; Estep JE; Miniard BM; Rudge TL; Peggins JO; Broadt TL; Wang M; Preuss MA; Siegal GP; Hemminki A; Harris RD; Aurigemma R; Curiel DT; Alvarez RD
Hum Gene Ther; 2011 Jul; 22(7):821-8. PubMed ID: 21171861
[TBL] [Abstract][Full Text] [Related]
37. Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.
Rein DT; Volkmer A; Bauerschmitz G; Beyer IM; Janni W; Fleisch MC; Welter AK; Bauerschlag D; Schöndorf T; Breidenbach M
J Cancer Res Clin Oncol; 2012 Apr; 138(4):603-10. PubMed ID: 22209976
[TBL] [Abstract][Full Text] [Related]
38. A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.
Hakkarainen T; Hemminki A; Curiel DT; Wahlfors J
Int J Mol Med; 2006 Oct; 18(4):751-9. PubMed ID: 16964432
[TBL] [Abstract][Full Text] [Related]
39. Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses.
Höti N; Chowdhury WH; Mustafa S; Ribas J; Castanares M; Johnson T; Liu M; Lupold SE; Rodriguez R
Cancer Gene Ther; 2010 Aug; 17(8):585-97. PubMed ID: 20448671
[TBL] [Abstract][Full Text] [Related]
40. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
